652153-43-0

Upstream product

• 405939-30-2 [3-(tert-butyldimethylsiloxy)propyl](4-(trimethylstannanyl)pyridin-2-yl)carbamic acid tert-butyl ester 
• 652153-34-9 (3-chlorophenyl)-(4-chloro-[1,3,5]triazin-2-yl)carbamic acid tert-butyl ester 
• 405939-28-8 (4-iodopyridin-2-yl)carbamic acid tert-butyl ester 
• 108-42-9 3-chloro-aniline 
• 5330-63-2 t-butyl 3-chlorophenylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 405939-79-9 4-iodo-2-nicotinic acid 
• 405939-29-9 [3-(tert-butyldimethylsilanyloxy)propyl]-(4-iodopyridin-2-yl)carbamic acid tert-butyl ester 

Downstream Products

• 652153-35-0 3-((4-(4-((3-chlorophenyl)amino)-1,3,5-triazin-2-yl)-2-pyridinyl)amino)-1-propanol 

Relevant academic research and scientific papers

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors

On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and

SUBSTITUTED TRIAZINE KINASE INHIBITORS

The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.